- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Pharma Pulse 7/25/24: Driving CAR-Ts for Treatment in Cancer and Immunology, CrowdStrike Explains What Went Wrong in Global Outage & more
The latest news for pharma industry insiders.
Driving CAR-Ts for Treatment in Cancer and Immunology
A deep dive into why this therapy has demonstrated effectiveness in various areas, including for tumors.
Ongoing Stigma Remains a Major Obstacle in the Fight Against HIV | AIDS 2024
At the 25th annual international AIDS Conference in Munich, Germany, a group of international experts discussed the impact of HIV-related stigma and discrimination on efforts to end the HIV pandemic as a public health threat by 2030.
CrowdStrike Explains What Went Wrong Days After Global Tech Outage
Cybersecurity company lays out steps to prevent future quality-control disruptions.
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis.
Great insights by Abid Rahman from EVERSANA on the power of #AIas it revolutionizes operations across many industries, including #pharma. Always great to see a publication like Pharmaceutical Executive want to connect with experts.
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
